Literature DB >> 6173112

In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.

C P Spears, A H Shahinian, R G Moran, C Heidelberger, T H Corbett.   

Abstract

The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A. Thymidylate synthetase (TS) was determined by a tritiated 5-fluoro-2'-deoxyuridylate (FdUMP)-binding assay. Bolus 5-FUra (80 mg/kg, i.p.) administrated caused in all tumors a rapid decrease in free TS levels. Only Tumor 38, however, showed inhibition of TS to undetectable (less than 0.05 pmol/g) levels, which lasted up to 6 hr after treatment; correction for dissociation of endogenous TS: FdUMP:folate ternary complex during the TS assay was required. Total TS (free enzyme plus ternary complex) was determined with experimental conditions that achieved quantitative recovery of free TS from ternary complex. By 48 hr after 5-FUra, Tumor 38 showed a decrease in total TS proportional to the estimated log kill/dose of 5-FUra; in contrast, the resistant tumors showed no such decrease from pretreatment levels. Assay of FdUMP showed that the free nucleotide was formed rapidly in all tumors in excess over available TS-binding sites. However, tumor sensitivity did not correlate with peak or residual FdUMP levels or with deoxyuridylate levels, which were low and remained so in all tumors. Tumor sensitivity to 5-FUra also could not be explained by the small differences among the tumors in total perchloric acid-soluble metabolites of 5-FUra or drug incorporation into RNA. We conclude from these data that levels of free TS in the tumor after 5-FUra treatment are predictive of chemotherapeutic response in these murine models of human colonic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6173112

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Fundamental pharmacokinetic limits on the utility of using a sinusoidal drug delivery system to enhance therapy.

Authors:  R R Burnette
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Effects of experimental chemoendocrine therapy with a combination of a pure antiestrogen and 5-fluorouracil on human breast cancer cells implanted in nude mice.

Authors:  Y Ogasawara; H Doihara; K Shiroma; Y Kanaya; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

3.  Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.

Authors:  Hiroaki Tsujimoto; Sayaka Tsukioka; Satoru Ono; Etsuko Sakamoto; Kazuki Sakamoto; Kohji Tsuta; Fumio Nakagawa; Hitoshi Saito; Junji Uchida; Mamoru Kiniwa; Masakazu Fukushima
Journal:  Oncol Lett       Date:  2010-09-17       Impact factor: 2.967

Review 4.  Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy.

Authors:  Valerie M Nelson; Al B Benson
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

5.  Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients.

Authors:  K Komaki; Y Kamamura; Y Ohmine; M Sasa; K Tanaka; H Inoue; T Uyama; T Morimoto; Y Monden
Journal:  Breast Cancer Res Treat       Date:  1995-08       Impact factor: 4.872

6.  Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects.

Authors:  Toshihiro Komura; Koh Miura; Tetsuhiko Shirasaka; Shinobu Ohnuma; Miki Shimada; Taiki Kajiwara; Fumiyoshi Fujishima; Alex Philchenkov; Kei Nakagawa; Katsuyoshi Kudoh; Sho Haneda; Masahide Toshima; Atsushi Kohyama; Hiroaki Musha; Takeshi Naitoh; Chikashi Shibata; Michiaki Unno
Journal:  Int J Clin Oncol       Date:  2014-05-08       Impact factor: 3.402

Review 7.  Cellular pharmacology of fluorinated pyrimidines in vivo in man.

Authors:  J S Kovach; R W Beart
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

Review 8.  Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Authors:  P J Houghton; J A Houghton; B J Hazelton; S Radparvar
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

9.  A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.

Authors:  T Inada; Y Ogata; T Kubota; I Ozawa; S Hishinuma; H Shimizu; K Kotake; T Ikeda; Y Koyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

10.  Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.

Authors:  E Chu; D M Koeller; J L Casey; J C Drake; B A Chabner; P C Elwood; S Zinn; C J Allegra
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.